盐酸川芎嗪联合替格瑞洛治疗冠心病心绞痛的临床疗效

Clinical effect of ligustrazine hydrochloride combined with ticagrelor in the treatment of coronary heart disease angina pectoris

目的观察盐酸川芎嗪联合替格瑞洛治疗冠心病心绞痛的临床疗效。方法选取2019年1月—2021年6月安福县人民医院收治的60例冠心病心绞痛患者作为研究对象,按照随机对照原则分为对照组与观察组,每组30例。对照组予以替格瑞洛,观察组在对照组基础上予以盐酸川芎嗪,2组均持续用药30 d。比较2组临床疗效,治疗前及治疗30 d后心绞痛症状[心绞痛发作次数、发作持续时间及视觉模拟评分法(VAS)评分]、心功能指标[左心室射血分数(LVEF)、心排血量(CO)、每搏输出量(SV)]、血清炎性因子[白介素6(IL?6)、同型半胱氨酸(Hcy)、缺血修饰白蛋白(IMA)]水平,硝酸甘油总用量,并观察2组不良反应发生情况。结果观察组治疗后总有效率为90.00%,高于对照组的70.00%(χ^(2)=12.500,P<0.001)。治疗30 d后,2组心绞痛发作次数少于治疗前,心绞痛发作持续时间短于治疗前,VAS评分低于治疗前,且观察组心绞痛发作次数少于对照组,心绞痛发作持续时间短于对照组,VAS评分低于对照组(P<0.01)。观察组硝酸甘油总用量少于对照组(P<0.01)。治疗30 d后,2组LVEF、CO、SV高于治疗前,且观察组高于对照组(P<0.05)。治疗30 d后,2组血清IL?6、Hcy、IMA水平低于治疗前,且观察组低于对照组(P<0.01)。观察组不良反应总发生率为20.00%,与对照组的13.33%比较,差异无统计学意义(χ^(2)=0.480,P=0488)。结论盐酸川芎嗪联合替格瑞洛治疗冠心病心绞痛的临床疗效确切,可有效改善心绞痛症状和心功能,减轻疼痛程度及炎性反应,且安全性较高。

Objective To observe clinical effect of ligustrazine hydrochloride combined with ticagrelor in the treatment of coronary heart disease angina pectoris.Methods A total of 60 cases of patients with coronary heart disease angina pectoris were selected from January 2019 to June 2021 in Anfu County People′s Hospital,which were randomly divided into control group and observation group according to the principle of random control,with 30 cases in each group.The control group was given ticagrelor,and the observation group was given ligustrazine hydrochloride on the basis of the control group.Both groups continued to take medicine for 30 days.Clinical efficacy,angina pectoris symptoms(angina pectoris of attack times,attack duration and VAS score),cardiac function indexes(LVEF,CO,SV),serum inflammatory response indexes(IL6,Hcy,IMA)before treatment and after treatment for 30 days,total dosage of nitroglycerin were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate in the observation group was 90.00%,was higher than 70.00%in the control group(χ^(2)=12.500,P<0.001).After 30 days of treatment,the times and duration of attacks in the two groups were less than those before treatment,and the VAS score was lower than that before treatment,the times and duration of attacks in the observation group were less than those in the control group,and the VAS score was lower than that in the control group(P<0.01).The total dosage of nitroglycerin in the observation group was less than that in the control group(P<0.01).After 30 days of treatment,LVEF,CO and SV in the two groups were higher than those before treatment,and those in the observation group were higher than control group(P<0.05).After 30 days of treatment,the levels of serum IL6,Hcy and IMA in the two groups were lower than those before treatment,and those in the observation group were lower than control group(P<0.01).The total incidence of adverse reactions in the observation group was 2000%,compared with 13.33%in the control group,the difference was not statistically significant(χ^(2)=0.480,P=0488).Conclusion Ligustrazine hydrochloride combined with ticagrelor have an exact clinical effect for coronary heart disease angina pectoris,which can effectively improve angina pectoris symptoms and cardiac function,reduce pain degree and inflammatory reaction,and with high safety.